# A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

> **NCT03204019** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Tegafur and Temozolomide
- **DRUG:** Tegafur and Temozolomide combined with Thalidomide

## Key facts

- **NCT ID:** NCT03204019
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2017-10
- **Final completion:** 2018-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204019, "A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03204019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*